{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:19:14Z","timestamp":1788556754754,"version":"build-2803163510"},"reference-count":119,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and purpose: To review available data on toxicity during and\/or after treatment of abdominal-pelvic lymph node oligometastases (A-P LN) with stereotactic body radiation therapy (SBRT) and to provide an overview of adverse events and its relation to dose or fractionation.\nMaterial and methods: For this systematic review, we searched MEDLINE, Embase, Web of Science Core Collection, and CINAH for studies published between the database inception and October 3rd, 2023. Inclusion criteria were (1) patients with 1\u20135 A-P LN oligometastases, (2) treatment with SBRT to a median prescribed dose of \u226555 Gy BED10, and (3) description of acute and\/or late toxicity. There were no language or date restrictions.\nResults: A total of 35 studies, including 1,512 patients, were selected. Late grade 3 and 4 adverse events occurred in 0.6% and 0.1% of the patients treated for A-P LN oligometastases. All late adverse events grade \u2265 3 occurred after treatment of the tumor with a minimum BED10 of 72 Gy. Of the 11 patients with severe late toxicity, five patients were re-irradiated. Late grade 2 and 1 toxicity was reported in 3.4% and 8.3% of the patients. Acute toxicity grades 4, 3, 2, and 1 occurred in 0.1%, 0.2%, 4.4%, and 19.8% of the patients, respectively.\nInterpretation: SBRT for A-P LN oligometastases show low toxicity rates. Nearly 50% of late adverse events \u2265 grade 3 were associated with re-irradiation.<\/jats:p>","DOI":"10.2340\/1651-226x.2024.40681","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T02:13:09Z","timestamp":1730254389000},"page":"822-832","source":"Crossref","is-referenced-by-count":8,"title":["Stereotactic body radiation therapy on abdominal-pelvic lymph node oligometastases: a systematic review on toxicity"],"prefix":"10.2340","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3865-5692","authenticated-orcid":false,"given":"Lucy A.","family":"Van Werkhoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8333-7559","authenticated-orcid":false,"given":"Eugenio","family":"Cammareri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4264-9903","authenticated-orcid":false,"given":"Mischa S.","family":"Hoogeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8011-2982","authenticated-orcid":false,"given":"Remi A.","family":"Nout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1200-640X","authenticated-orcid":false,"given":"Maaike T.W.","family":"Milder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5021-1597","authenticated-orcid":false,"given":"Joost J.M.E.","family":"Nuyttens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"82603","doi-asserted-by":"crossref","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8\u201310.","DOI":"10.1200\/JCO.1995.13.1.8"},{"key":"82604","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/jco.1995.13.1.8","DOI":"10.1200\/JCO.1995.13.1.8"},{"key":"82605","doi-asserted-by":"crossref","unstructured":"Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378\u201382.","DOI":"10.1038\/nrclinonc.2011.44"},{"key":"82606","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nrclinonc.2011.44","DOI":"10.1038\/nrclinonc.2011.44"},{"key":"82607","doi-asserted-by":"crossref","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, Desouza NM, et al. Character-isation and classification of oligometastatic disease: a European Society for Ra-diotherapy and Oncology and European Organisation for Research and Treat-ment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18\u201328.","DOI":"10.1016\/S1470-2045(19)30718-1"},{"key":"82608","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/s1470-2045(19)30718-1","DOI":"10.1016\/S1470-2045(19)30718-1"},{"key":"82609","doi-asserted-by":"crossref","unstructured":"Kroeze SGC, Pavic M, Stellamans K, Lievens Y, Becherini C, Scorsetti M, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol. 2023;24(3):e121\u201332.","DOI":"10.1016\/S1470-2045(22)00752-5"},{"key":"82610","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/s1470-2045(22)00752-5","DOI":"10.1016\/S1470-2045(22)00752-5"},{"key":"82611","doi-asserted-by":"crossref","unstructured":"Takeda A, Sanuki N, Kunieda E. Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. World J Gastroenterol. 2014;20(15):4220\u20139.","DOI":"10.3748\/wjg.v20.i15.4220"},{"key":"82612","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3748\/wjg.v20.i15.4220","DOI":"10.3748\/wjg.v20.i15.4220"},{"key":"82613","doi-asserted-by":"crossref","unstructured":"Milano MT, Katz AW, Okunieff P. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. Am J Clin Oncol. 2010;33(2):157\u201363.","DOI":"10.1097\/COC.0b013e3181979238"},{"key":"82614","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/coc.0b013e3181979238","DOI":"10.1097\/COC.0b013e3181979238"},{"key":"82615","doi-asserted-by":"crossref","unstructured":"Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R, et al. The oligometastatic state \u2013 separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11(9):549\u201357.","DOI":"10.1038\/nrclinonc.2014.96"},{"key":"82616","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nrclinonc.2014.96","DOI":"10.1038\/nrclinonc.2014.96"},{"key":"82617","doi-asserted-by":"crossref","unstructured":"Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospec-tive, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021;22(1):98\u2013106.","DOI":"10.1016\/S1470-2045(20)30537-4"},{"key":"82618","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/s1470-2045(20)30537-4","DOI":"10.1016\/S1470-2045(20)30537-4"},{"key":"82619","doi-asserted-by":"crossref","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observa-tion vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE Phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650\u20139.","DOI":"10.1001\/jamaoncol.2020.0147"},{"key":"82620","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147","DOI":"10.1001\/jamaoncol.2020.0147"},{"key":"82621","doi-asserted-by":"crossref","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830\u20138.","DOI":"10.1200\/JCO.20.00818"},{"key":"82622","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/jco.20.00818","DOI":"10.1200\/JCO.20.00818"},{"key":"82623","doi-asserted-by":"crossref","unstructured":"Shahi J, Peng J, Donovan E, Vansantvoort J, Wong R, Tsakiridis T, et al. Overall and chemo-therapy-free survival following stereotactic body radiation therapy for abdom-inopelvic oligometastases. J Med Imaging Radiat Oncol. 2020;64(4):563\u20139.","DOI":"10.1111\/1754-9485.13057"},{"key":"82624","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1754-9485.13057","DOI":"10.1111\/1754-9485.13057"},{"key":"82625","doi-asserted-by":"crossref","unstructured":"Burkon P, Selingerova I, Slavik M, Pospisil P, Bobek L, Kominek L, et al. Stereotactic body radiotherapy for lymph node oligometastases: real-world evidence from 90 con-secutive patients. Front Oncol. 2020;10:616494.","DOI":"10.3389\/fonc.2020.616494"},{"key":"82626","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fonc.2020.616494","DOI":"10.3389\/fonc.2020.616494"},{"key":"82627","doi-asserted-by":"crossref","unstructured":"Kim MS, Cho CK, Yang KM, Lee DH, Moon SM, Shin YJ. Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer. World J Gas-troenterol. 2009;15(48):6091\u20135.","DOI":"10.3748\/wjg.15.6091"},{"key":"82628","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3748\/wjg.15.6091","DOI":"10.3748\/wjg.15.6091"},{"key":"82629","doi-asserted-by":"crossref","unstructured":"Jereczek-Fossa BA, Ronchi S, Orecchia R. Is Stereotactic Body Radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective? Rep Pract Oncol Ra-diother. 2015;20(6):472\u201383.","DOI":"10.1016\/j.rpor.2014.10.004"},{"key":"82630","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.rpor.2014.10.004","DOI":"10.1016\/j.rpor.2014.10.004"},{"key":"82631","doi-asserted-by":"crossref","unstructured":"Deodato F, Macchia G, Buwenge M, Bonetti M, Cilla S, Zamagni A, et al. Systematic review of stereotactic body radiotherapy for nodal metastases. Clin Exp Metastasis. 2021;38(1):11\u201329.","DOI":"10.1007\/s10585-020-10071-x"},{"key":"82632","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10585-020-10071-x","DOI":"10.1007\/s10585-020-10071-x"},{"key":"82633","doi-asserted-by":"crossref","unstructured":"Ponti E, Lancia A, Ost P, Trippa F, Triggiani L, Detti B, et al. Exploring all avenues for radio-therapy in oligorecurrent prostate cancer disease limited to lymph nodes: a sys-tematic review of the role of stereotactic body radiotherapy. Eur Urol Focus. 2017;3(6):538\u201344.","DOI":"10.1016\/j.euf.2017.07.006"},{"key":"82634","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euf.2017.07.006","DOI":"10.1016\/j.euf.2017.07.006"},{"key":"82635","doi-asserted-by":"crossref","unstructured":"Page MJ, Mckenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","DOI":"10.1136\/bmj.n71"},{"key":"82636","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"82637","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial [last updated October 2019]. In: Higgins JPT, Thomas J, Chan-dler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024."},{"key":"82638","doi-asserted-by":"crossref","unstructured":"Alsuhaibani A, Elashwah A, Alkafi A, Constantinescus C, F AL. Stereotactic Body Radia-tion Therapy (SBRT) using CyberKnife in oligometastatic cancer patients; retro-spective evaluation, single institution experience. J Gastrointest Cancer. 2019;50(4):879\u201387.","DOI":"10.1007\/s12029-018-0170-8"},{"key":"82639","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s12029-018-0170-8","DOI":"10.1007\/s12029-018-0170-8"},{"key":"82640","doi-asserted-by":"crossref","unstructured":"Barney BM, Olivier KR, Macdonald OK, Fong De Los Santos LE, Miller RC, et al. Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors. Am J Clin Oncol. 2012;35(6):537\u201342.","DOI":"10.1097\/COC.0b013e31821f876a"},{"key":"82641","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/COC.0b013e31821f876a","DOI":"10.1097\/COC.0b013e31821f876a"},{"key":"82642","doi-asserted-by":"crossref","unstructured":"Bignardi M, Navarria P, Mancosu P, Cozzi L, Fogliata A, Tozzi A, et al. Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metasta-ses. Int J Radiat Oncol Biol Phys. 2011;81(3):831\u20138.","DOI":"10.1016\/j.ijrobp.2010.05.032"},{"key":"82643","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijrobp.2010.05.032","DOI":"10.1016\/j.ijrobp.2010.05.032"},{"key":"82644","doi-asserted-by":"crossref","unstructured":"Bouman-Wammes EW, Van Dodewaard-De Jong JM, Dahele M, Cysouw MCF, Hoekstra OS, Van Moorselaar RJA, et al. Benefits of using stereotactic body radiotherapy in patients with metachronous oligometastases of hormone-sensitive prostate cancer detected by. Clin Genitourin Cancer. 2017;15(5):e773\u201382.","DOI":"10.1016\/j.clgc.2017.03.009"},{"key":"82645","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clgc.2017.03.009","DOI":"10.1016\/j.clgc.2017.03.009"},{"key":"82646","doi-asserted-by":"crossref","unstructured":"Caivano D, Bonome P, Pezzulla D, Rotondi M, Sigillo RC, De Sanctis V, et al. Stereotactic body radiation therapy for the treatment of lymph node metastases: a retrospec-tive mono-institutional study in a large cohort of patients. Front Oncol. 2023;13:1163213.","DOI":"10.3389\/fonc.2023.1163213"},{"key":"82647","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fonc.2023.1163213","DOI":"10.3389\/fonc.2023.1163213"},{"key":"82648","doi-asserted-by":"crossref","unstructured":"Corvo R, Lamanna G, Vagge S, Belgioia L, Bosetti D, Aloi D, et al. Once-weekly stereotactic radiotherapy for patients with oligometastases: compliance and preliminary efficacy. Tumori. 2013;99(2):159\u201363.","DOI":"10.1177\/030089161309900207"},{"key":"82649","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/030089161309900207","DOI":"10.1177\/030089161309900207"},{"key":"82650","doi-asserted-by":"crossref","unstructured":"Cozzi S, Botti A, Timon G, Blandino G, Najafi M, Manicone M, et al. Prognostic factors, effi-cacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : an investigation of 117 pelvic lymph nodes. Strahlenther Onkol. 2022;198(8):700\u20139.","DOI":"10.1007\/s00066-021-01871-5"},{"key":"82651","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00066-021-01871-5","DOI":"10.1007\/s00066-021-01871-5"},{"key":"82652","doi-asserted-by":"crossref","unstructured":"Cuccia F, Tamburo M, Piras A, Mortellaro G, Iudica A, Daidone A, et al. Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience. Medicina-Lithuania. 2023;59.","DOI":"10.3390\/medicina59081442"},{"key":"82653","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/medicina59081442","DOI":"10.3390\/medicina59081442"},{"key":"82654","doi-asserted-by":"crossref","unstructured":"Detti B, Bonomo P, Masi L, Doro R, Cipressi S, Iermano C, et al. Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer. World J Urol. 2015;33(8):1197\u2013203.","DOI":"10.1007\/s00345-014-1427-x"},{"key":"82655","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00345-014-1427-x","DOI":"10.1007\/s00345-014-1427-x"},{"key":"82656","doi-asserted-by":"crossref","unstructured":"Franzese C, Lopci E, Di Brina L, D\u2019agostino GR, Navarria P, Mancosu P, et al. 11C-choline-pet guided stereotactic body radiation therapy for lymph node metastases in oli-gometastatic prostate cancer. Cancer Invest. 2017;35(9):586\u201393.","DOI":"10.1080\/07357907.2017.1375116"},{"key":"82657","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/07357907.2017.1375116","DOI":"10.1080\/07357907.2017.1375116"},{"key":"82658","doi-asserted-by":"crossref","unstructured":"Franzese C, Fogliata A, Comito T, Tozzi A, Iftode C, Clerici E, et al. Stereotac-tic\/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. Br J Radiol. 2017;90(1079):20170422.","DOI":"10.1259\/bjr.20170422"},{"key":"82659","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1259\/bjr.20170422","DOI":"10.1259\/bjr.20170422"},{"key":"82660","doi-asserted-by":"crossref","unstructured":"Franzese C, Cozzi L, Franceschini D, D\u2019agostino G, Comito T, De Rose F, et al. Role of Ste-reotactic body radiation therapy with volumetric-modulated arcs and high-intensity photon beams for the treatment of abdomino-pelvic lymph-node me-tastases. Cancer Invest. 2016;34(7):348\u201354.","DOI":"10.1080\/07357907.2016.1197235"},{"key":"82661","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/07357907.2016.1197235","DOI":"10.1080\/07357907.2016.1197235"},{"key":"82662","doi-asserted-by":"crossref","unstructured":"Franzese C, Comito T, Tripoli A, Franceschini D, Clerici E, Navarria P, et al. Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases. Clin Exp Metastasis. 2020;37(5):565\u201373.","DOI":"10.1007\/s10585-020-10047-x"},{"key":"82663","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10585-020-10047-x","DOI":"10.1007\/s10585-020-10047-x"},{"key":"82664","doi-asserted-by":"crossref","unstructured":"Gawish A, Abdullayev N, El-Arayedh S, R\u00f6llich B, Ochel HJ, Brunner TB. Metabolic re-sponse after 68Ga-PSMA-PET\/CT-directed IGRT\/SBRT for oligometastases pros-tate cancer. Clin Transl Oncol. 2023;25(4):987\u201394.","DOI":"10.1007\/s12094-022-03002-7"},{"key":"82665","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s12094-022-03002-7","DOI":"10.1007\/s12094-022-03002-7"},{"key":"82666","doi-asserted-by":"crossref","unstructured":"Ingrosso G, Trippa F, Maranzano E, Carosi A, Ponti E, Arcidiacono F, et al. Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol. 2017;35(1):45\u20139.","DOI":"10.1007\/s00345-016-1860-0"},{"key":"82667","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00345-016-1860-0","DOI":"10.1007\/s00345-016-1860-0"},{"key":"82668","doi-asserted-by":"crossref","unstructured":"Kang JK, Kim MS, Kim JH, Yoo SY, Cho CK, Yang KM, et al. Oligometastases confined one organ from colorectal cancer treated by SBRT. Clin Exp Metastasis. 2010;27(4):273\u20138.","DOI":"10.1007\/s10585-010-9325-0"},{"key":"82669","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10585-010-9325-0","DOI":"10.1007\/s10585-010-9325-0"},{"key":"82670","doi-asserted-by":"crossref","unstructured":"Kneebone A, Hruby G, Ainsworth H, Byrne K, Brown C, Guo L, et al. Stereotactic body ra-diotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography. Eur Urol Oncol. 2018;1(6):531\u20137.","DOI":"10.1016\/j.euo.2018.04.017"},{"key":"82671","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euo.2018.04.017","DOI":"10.1016\/j.euo.2018.04.017"},{"key":"82672","doi-asserted-by":"crossref","unstructured":"Kutuk T, Herrera R, Mustafayev TZ, Gungor G, Ugurluer G, Atalar B, et al. Multi-institutional outcomes of stereotactic magnetic resonance image guided adaptive radiation therapy with a median biologically effective dose of 100 Gy10 for non-bone oli-gometastases. Adv Radiat Oncol. 2022;7(6):100978.","DOI":"10.1016\/j.adro.2022.100978"},{"key":"82673","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.adro.2022.100978","DOI":"10.1016\/j.adro.2022.100978"},{"key":"82674","doi-asserted-by":"crossref","unstructured":"Lepinoy A, Silva YE, Martin E, Bertaut A, Quivrin M, Aubignac L, et al. Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET\/CT oligorecurrent nodal failures from prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(1):40\u20138.","DOI":"10.1007\/s00259-018-4159-0"},{"key":"82675","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00259-018-4159-0","DOI":"10.1007\/s00259-018-4159-0"},{"key":"82676","doi-asserted-by":"crossref","unstructured":"Loi M, Di Cataldo V, Francolini G, Bonomo P, Masi L, Simontacchi G, et al. Single-Fraction stereotactic body radiotherapy for oligometastatic lymph node relapse in pros-tate cancer. Oncol Res Treat. 2018;41(11):703\u20135.","DOI":"10.1159\/000491605"},{"key":"82677","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000491605","DOI":"10.1159\/000491605"},{"key":"82678","doi-asserted-by":"crossref","unstructured":"Loi M, Frelinghuysen M, Klass ND, Oomen-De Hoop E, Granton PV, Aerts J, et al. Locore-gional control and survival after lymph node SBRT in oligometastatic disease. Clin Exp Metastasis. 2018;35(7):625\u201333.","DOI":"10.1007\/s10585-018-9922-x"},{"key":"82679","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10585-018-9922-x","DOI":"10.1007\/s10585-018-9922-x"},{"key":"82680","doi-asserted-by":"crossref","unstructured":"Matoba M, Tsuchiya H, Kondo T, Ota K. Stereotactic body radiotherapy delivered with IMRT for oligometastatic regional lymph node metastases in hepatocellular car-cinoma: a single-institutional study. J Radiat Res (Tokyo). 2020;61(5):776\u201383.","DOI":"10.1093\/jrr\/rraa067"},{"key":"82681","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/jrr\/rraa067","DOI":"10.1093\/jrr\/rraa067"},{"key":"82682","doi-asserted-by":"crossref","unstructured":"Nicosia L, Trapani G, Rigo M, Fiorini M, Giaj-Levra N, Mazzola R, et al. 1.5 T MR-Guided Daily Adapted SBRT on Lymph Node Oligometastases from Prostate Cancer. Journal of Clinical Medicine. 2022;11.","DOI":"10.20944\/preprints202210.0205.v1"},{"key":"82683","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/jcm11226658","DOI":"10.3390\/jcm11226658"},{"key":"82684","doi-asserted-by":"crossref","unstructured":"Ost P, Jereczek-Fossa BA, Van As N, Zilli T, Tree A, Henderson D, et al. Pattern of progres-sion after stereotactic body radiotherapy for oligometastatic prostate cancer nodal recurrences. Clin Oncol (R Coll Radiol). 2016;28(9):e115\u201320.","DOI":"10.1016\/j.clon.2016.04.040"},{"key":"82685","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clon.2016.04.040","DOI":"10.1016\/j.clon.2016.04.040"},{"key":"82686","unstructured":"Park HJ, Chang AR, Seo Y, Cho CK, Jang WI, Kim MS, et al. Stereotactic body radiotherapy for recurrent or oligometastatic uterine cervix cancer: a cooperative study of the Korean Radiation Oncology Group (KROG 14-11). Anticancer Res. 2015;35(9):5103\u201310."},{"key":"82687","doi-asserted-by":"crossref","unstructured":"Pasqualetti F, Panichi M, Sainato A, Matteucci F, Galli L, Cocuzza P, et al. [18F]Choline PET\/CT and stereotactic body radiotherapy on treatment decision making of oli-gometastatic prostate cancer patients: preliminary results. Radiat Oncol. 2016;11(1):46-51.","DOI":"10.1186\/s13014-016-0586-x"},{"key":"82688","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s13014-016-0586-x","DOI":"10.1186\/s13014-016-0586-x"},{"key":"82689","doi-asserted-by":"crossref","unstructured":"Pezzulla D, Macchia G, Cilla S, Buwenge M, Ferro M, Bonome P, et al. Stereotactic body ra-diotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials. Clin Exp Me-tastasis. 2021;38(6):519\u201326.","DOI":"10.1007\/s10585-021-10126-7"},{"key":"82690","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s10585-021-10126-7","DOI":"10.1007\/s10585-021-10126-7"},{"key":"82691","doi-asserted-by":"crossref","unstructured":"Regnery S, Buchele C, Piskorski L, Weykamp F, Held T, Eichkorn T, et al. SMART ablation of lymphatic oligometastases in the pelvis and abdomen: clinical and dosimetry outcomes. Radiother Oncol. 2022;168:106\u201312.","DOI":"10.1016\/j.radonc.2022.01.038"},{"key":"82692","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.radonc.2022.01.038","DOI":"10.1016\/j.radonc.2022.01.038"},{"key":"82693","doi-asserted-by":"crossref","unstructured":"Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J, et al. Stereotactic Abative Body Radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 2018;74(4):455\u201362.","DOI":"10.1016\/j.eururo.2018.06.004"},{"key":"82694","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2018.06.004","DOI":"10.1016\/j.eururo.2018.06.004"},{"key":"82695","doi-asserted-by":"crossref","unstructured":"Wang Z, Wang J, Zhuang H, Wang P, Yuan Z. Stereotactic body radiation therapy induces fast tumor control and symptom relief in patients with iliac lymph node metas-tasis. Sci Rep. 2016;6:37987.","DOI":"10.1038\/srep37987"},{"key":"82696","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/srep37987","DOI":"10.1038\/srep37987"},{"key":"82697","doi-asserted-by":"crossref","unstructured":"Werensteijn-Honingh AM, Wevers AFJ, Peters M, Kroon PS, Intven M, Eppinga WSC, et al. Progression-free survival in patients with 68Ga-PSMA-PET-directed SBRT for lymph node oligometastases. Acta Oncol. 2021;60(10):1342\u201351.","DOI":"10.1080\/0284186X.2021.1955970"},{"key":"82698","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186x.2021.1955970","DOI":"10.1080\/0284186X.2021.1955970"},{"key":"82699","doi-asserted-by":"crossref","unstructured":"Yang DD, Brennan VS, Huynh E, Williams CL, Han Z, Ampofo N, et al. Stereotactic Magnet-ic Resonance-Guided Adaptive Radiation Therapy (SMART) for abdominopelvic oligometastases. Int J Radiat Oncol Biol Phys. 2022;114(5):941\u20139.","DOI":"10.1016\/j.ijrobp.2022.05.016"},{"key":"82700","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.016","DOI":"10.1016\/j.ijrobp.2022.05.016"},{"key":"82701","doi-asserted-by":"crossref","unstructured":"Yeung R, Hamm J, Liu M, Schellenberg D. Institutional analysis of stereotactic body radio-therapy (SBRT) for oligometastatic lymph node metastases. Radiat Oncol. 2017;12(1):105.","DOI":"10.1186\/s13014-017-0820-1"},{"key":"82702","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s13014-017-0820-1","DOI":"10.1186\/s13014-017-0820-1"},{"key":"82703","doi-asserted-by":"crossref","unstructured":"Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37(8):4078\u2013101.","DOI":"10.1118\/1.3438081"},{"key":"82704","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1118\/1.3438081","DOI":"10.1118\/1.3438081"},{"key":"82705","doi-asserted-by":"crossref","unstructured":"Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, et al. Stereotactic radi-otherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115(3):665\u201372.","DOI":"10.1002\/cncr.24059"},{"key":"82706","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/cncr.24059","DOI":"10.1002\/cncr.24059"},{"key":"82707","doi-asserted-by":"crossref","unstructured":"Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823\u201330.","DOI":"10.1080\/02841860600904854"},{"key":"82708","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/02841860600904854","DOI":"10.1080\/02841860600904854"},{"key":"82709","doi-asserted-by":"crossref","unstructured":"Lo SS, Teh BS, Lu JJ, Schefter TE. Stereotactic body radiation therapy. Berlin: Springer; 2012.","DOI":"10.1007\/978-3-642-25605-9"},{"key":"82710","doi-asserted-by":"crossref","unstructured":"De Pooter JA, Mendez Romero A, Wunderink W, Storchi PR, Heijmen BJ. Automated non-coplanar beam direction optimization improves IMRT in SBRT of liver metastasis. Radiother Oncol. 2008;88(3):376\u201381.","DOI":"10.1016\/j.radonc.2008.06.001"},{"key":"82711","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.radonc.2008.06.001","DOI":"10.1016\/j.radonc.2008.06.001"},{"key":"82712","doi-asserted-by":"crossref","unstructured":"Hanna GG, Murray L, Patel R, Jain S, Aitken KL, Franks KN, et al. UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol (R Coll Radiol). 2018;30(1):5\u201314.","DOI":"10.1016\/j.clon.2017.09.007"},{"key":"82713","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clon.2017.09.007","DOI":"10.1016\/j.clon.2017.09.007"},{"key":"82714","doi-asserted-by":"crossref","unstructured":"Timmerman RD. An overview of hypofractionation and introduction to this issue of. Semin Radiat Oncol. 2008;18(4):215\u201322.","DOI":"10.1016\/j.semradonc.2008.04.001"},{"key":"82715","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.semradonc.2008.04.001","DOI":"10.1016\/j.semradonc.2008.04.001"},{"key":"82716","doi-asserted-by":"crossref","unstructured":"Pasqualetti F, Trippa F, Aristei C, Borghesi S, Colosimo C, Cantarella M, et al. Stereotactic radiotherapy for oligometastases in the lymph nodes. Rep Pract Oncol Radi-other. 2022;27(1):46\u201351.","DOI":"10.5603\/RPOR.a2022.0007"},{"key":"82717","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5603\/rpor.a2022.0007","DOI":"10.5603\/RPOR.a2022.0007"},{"key":"82718","doi-asserted-by":"crossref","unstructured":"Jereczek-Fossa BA, Muto M, Durante S, Ferrari A, Piperno G, Fodor C, et al. Stereotactic body radiation therapy for mediastinal lymph node metastases: how do we fly in a \u2018no-fly zone\u2019? Acta Oncol. 2018;57(11):1532\u20139.","DOI":"10.1080\/0284186X.2018.1486040"},{"key":"82719","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186x.2018.1486040","DOI":"10.1080\/0284186X.2018.1486040"},{"key":"82720","doi-asserted-by":"crossref","unstructured":"Song JW, Chung KC. Observational studies: cohort and case-control studies. Plast Re-constr Surg. 2010;126(6):2234\u201342.","DOI":"10.1097\/PRS.0b013e3181f44abc"},{"key":"82721","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/prs.0b013e3181f44abc","DOI":"10.1097\/PRS.0b013e3181f44abc"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/40681\/48075","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/40681\/48075","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:04:58Z","timestamp":1756404298000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/40681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":119,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2024.40681","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]}}}